Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study

H. Ralph Schumacher; Robert R. Evans; Kenneth G. Saag; James Clower; William Jennings; Steven P. Weinstein; George D. Yancopoulos; Jian Wang; Robert Terkeltaub

doi:10.1002/acr.21690

Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study

Arthritis Care & Research ◽

10.1002/acr.21690 ◽

2012 ◽

Vol 64 (10) ◽

pp. 1462-1470 ◽

Cited By ~ 70

Author(s):

H. Ralph Schumacher ◽

Robert R. Evans ◽

Kenneth G. Saag ◽

James Clower ◽

William Jennings ◽

...

Keyword(s):

Uric Acid ◽

Interleukin 1 ◽

Phase Iii ◽

Efficacy Study ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Therapy ◽

Gout Flares

Download Full-text

Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.33412 ◽

2012 ◽

Vol 64 (3) ◽

pp. 876-884 ◽

Cited By ~ 70

Author(s):

H. Ralph Schumacher ◽

John S. Sundy ◽

Robert Terkeltaub ◽

Howard R. Knapp ◽

Scott J. Mellis ◽

...

Keyword(s):

Phase Ii ◽

Controlled Trial ◽

Interleukin 1 ◽

Acute Gout ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Therapy ◽

Gout Flares

Download Full-text

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

JAMA ◽

10.1001/jama.271.23.1836 ◽

1994 ◽

Vol 271 (23) ◽

pp. 1836-1843 ◽

Cited By ~ 136

Author(s):

C. J. Fisher

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Sepsis Syndrome ◽

Phase Iii ◽

Study Group ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Trial Phase

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Faculty Opinions recommendation of Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1090830.544164 ◽

2007 ◽

Author(s):

Nico van Zandwijk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Controlled Study ◽

Small Cell Lung ◽

Extensive Disease ◽

Double Blind ◽

Double Blind Placebo ◽

Response To Chemotherapy

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Download Full-text

Faculty Opinions recommendation of Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962498.793465528 ◽

2012 ◽

Author(s):

David Alpers

Keyword(s):

Peritoneal Carcinomatosis ◽

Bowel Obstruction ◽

Symptomatic Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717996902.793477633 ◽

2013 ◽

Author(s):

Virginia Kraus

Keyword(s):

Hip Pain ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Faculty of 1000 evaluation for Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718030851.793482493 ◽

2013 ◽

Author(s):

Joanne Jordan ◽

Amanda Nelson

Keyword(s):

Clinical Trial ◽

Sustained Release ◽

Hip Osteoarthritis ◽

Randomised Clinical Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Parallel Group

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text